David Roman
Stock Analyst at Goldman Sachs
(1.73)
# 2,871
Out of 4,754 analysts
31
Total ratings
33.33%
Success rate
-6.68%
Average return
Main Sectors:
Stocks Rated by David Roman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TDOC Teladoc Health | Maintains: Buy | $16 → $13 | $9.43 | +37.86% | 3 | Mar 3, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $42 → $24 | $20.78 | +15.50% | 2 | Mar 3, 2025 | |
| SOLV Solventum | Maintains: Sell | $63 → $71 | $80.16 | -11.43% | 4 | Mar 3, 2025 | |
| LIVN LivaNova | Maintains: Buy | $64 → $55 | $41.72 | +31.83% | 2 | Mar 3, 2025 | |
| BAX Baxter International | Reinstates: Buy | $42 | $34.86 | +20.48% | 3 | Feb 26, 2025 | |
| IRTC iRhythm Technologies | Maintains: Neutral | $91 → $124 | $109.10 | +13.66% | 2 | Feb 24, 2025 | |
| DOCS Doximity | Maintains: Neutral | $58 → $80 | $68.45 | +16.87% | 2 | Feb 10, 2025 | |
| SYK Stryker | Maintains: Neutral | $384 → $427 | $394.88 | +8.13% | 2 | Jan 30, 2025 | |
| EW Edwards Lifesciences | Maintains: Buy | $81 → $90 | $71.39 | +26.07% | 3 | Dec 5, 2024 | |
| HQY HealthEquity | Initiates: Neutral | $108 | $104.82 | +3.03% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $90 | $104.87 | -14.18% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $500 | $566.98 | -11.81% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $121 | $140.22 | -13.71% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $274 | $228.45 | +19.94% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $129 | $105.38 | +22.41% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $83 | $94.30 | -11.98% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $87 | $86.45 | +0.64% | 1 | May 30, 2024 |
Teladoc Health
Mar 3, 2025
Maintains: Buy
Price Target: $16 → $13
Current: $9.43
Upside: +37.86%
Tandem Diabetes Care
Mar 3, 2025
Maintains: Neutral
Price Target: $42 → $24
Current: $20.78
Upside: +15.50%
Solventum
Mar 3, 2025
Maintains: Sell
Price Target: $63 → $71
Current: $80.16
Upside: -11.43%
LivaNova
Mar 3, 2025
Maintains: Buy
Price Target: $64 → $55
Current: $41.72
Upside: +31.83%
Baxter International
Feb 26, 2025
Reinstates: Buy
Price Target: $42
Current: $34.86
Upside: +20.48%
iRhythm Technologies
Feb 24, 2025
Maintains: Neutral
Price Target: $91 → $124
Current: $109.10
Upside: +13.66%
Doximity
Feb 10, 2025
Maintains: Neutral
Price Target: $58 → $80
Current: $68.45
Upside: +16.87%
Stryker
Jan 30, 2025
Maintains: Neutral
Price Target: $384 → $427
Current: $394.88
Upside: +8.13%
Edwards Lifesciences
Dec 5, 2024
Maintains: Buy
Price Target: $81 → $90
Current: $71.39
Upside: +26.07%
HealthEquity
Nov 15, 2024
Initiates: Neutral
Price Target: $108
Current: $104.82
Upside: +3.03%
May 30, 2024
Initiates: Buy
Price Target: $90
Current: $104.87
Upside: -14.18%
May 30, 2024
Initiates: Buy
Price Target: $500
Current: $566.98
Upside: -11.81%
May 30, 2024
Initiates: Buy
Price Target: $121
Current: $140.22
Upside: -13.71%
May 30, 2024
Initiates: Buy
Price Target: $274
Current: $228.45
Upside: +19.94%
May 30, 2024
Initiates: Neutral
Price Target: $129
Current: $105.38
Upside: +22.41%
May 30, 2024
Initiates: Sell
Price Target: $83
Current: $94.30
Upside: -11.98%
May 30, 2024
Initiates: Neutral
Price Target: $87
Current: $86.45
Upside: +0.64%